Prophylactic levofloxacin to prevent infections in newly diagnosed symptomatic myeloma: the TEAMM RCT

Mark T Drayson; Stella Bowcock; Tim Planche; Gulnaz Iqbal; Guy Pratt; Kwee Yong; Jill Wood; Kerry Raynes; Helen Higgins; Bryony Dawkins; David Meads; Claire T Hulme; Anna C Whittaker; Peter Hawkey; Eric Low; Janet A Dunn

doi:10.3310/hta23620

Prophylactic levofloxacin to prevent infections in newly diagnosed symptomatic myeloma: the TEAMM RCT

Mark T Drayson, Stella Bowcock, Tim Planche, Gulnaz Iqbal, Guy Pratt, Kwee Yong, Jill Wood, Kerry Raynes, Helen Higgins, Bryony Dawkins, David Meads, Claire T Hulme, Anna C Whittaker, Peter Hawkey, Eric Low, Janet A Dunn

Research output: Contribution to journal › Article › peer-review

2 Citations (Scopus)

213 Downloads (Pure)

Original language	English
Pages (from-to)	1-94
Journal	Health Technology Assessment
Volume	23
Issue number	62
DOIs	https://doi.org/10.3310/hta23620
Publication status	Published - Nov 2019

ASJC Scopus subject areas

Health Policy

Access to Document

10.3310/hta23620Licence: Other (please specify with Rights Statement)

TEAMM RCT
All NIHR Journals Library reports have been produced under the terms of a commissioning contract issued by the Secretary of State for Health. Reports may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Permission to reproduce material from a published report is covered by the UK government’s non-commercial licence for public sector information. Applications for commercial reproduction should be addressed to the editorial office at: [email protected] Taken from https://www.journalslibrary.nihr.ac.uk/rights_and_permissions/ on 16/01/2020
Final published version, 1.13 MBLicence: Other (please specify with Rights Statement)

https://www.journalslibrary.nihr.ac.uk/hta/hta23620

2 Citations
1 Article

Levofloxacin prophylaxis in patients with newly diagnosed myeloma (TEAMM): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial
TEAMM Trial Management Group and Trial Investigators, Drayson, M. T., Bowcock, S., Planche, T., Iqbal, G., Pratt, G., Yong, K., Wood, J., Raynes, K., Higgins, H., Dawkins, B., Meads, D., Hulme, C. T., Monahan, I., Karunanithi, K., Dignum, H., Belsham, E., Neilson, J., Harrison, B. & Lokare, A. & 6 others, Campbell, G., Hamblin, M., Hawkey, P., Whittaker, A. C., Low, E. & Dunn, J. A., Dec 2019, In: The Lancet Oncology. 20, 12, p. 1760-1772
Research output: Contribution to journal › Article › peer-review

Open Access
File
34 Citations (Scopus)

574 Downloads (Pure)

Cite this

Drayson, M. T., Bowcock, S., Planche, T., Iqbal, G., Pratt, G., Yong, K., Wood, J., Raynes, K., Higgins, H., Dawkins, B., Meads, D., Hulme, C. T., Whittaker, A. C., Hawkey, P., Low, E., & Dunn, J. A. (2019). Prophylactic levofloxacin to prevent infections in newly diagnosed symptomatic myeloma: the TEAMM RCT. Health Technology Assessment, 23(62), 1-94. https://doi.org/10.3310/hta23620

@article{e5457396b6ec4328815c81b2e2b4c814,

title = "Prophylactic levofloxacin to prevent infections in newly diagnosed symptomatic myeloma: the TEAMM RCT",

author = "Drayson, {Mark T} and Stella Bowcock and Tim Planche and Gulnaz Iqbal and Guy Pratt and Kwee Yong and Jill Wood and Kerry Raynes and Helen Higgins and Bryony Dawkins and David Meads and Hulme, {Claire T} and Whittaker, {Anna C} and Peter Hawkey and Eric Low and Dunn, {Janet A}",

year = "2019",

month = nov,

doi = "10.3310/hta23620",

language = "English",

volume = "23",

pages = "1--94",

journal = "Health Technology Assessment",

issn = "1366-5278",

publisher = "NIHR Health Technology Assessment Programme",

number = "62",

}

Drayson, MT, Bowcock, S, Planche, T, Iqbal, G, Pratt, G, Yong, K, Wood, J, Raynes, K, Higgins, H, Dawkins, B, Meads, D, Hulme, CT, Whittaker, AC, Hawkey, P, Low, E & Dunn, JA 2019, 'Prophylactic levofloxacin to prevent infections in newly diagnosed symptomatic myeloma: the TEAMM RCT', Health Technology Assessment, vol. 23, no. 62, pp. 1-94. https://doi.org/10.3310/hta23620

TY - JOUR

T1 - Prophylactic levofloxacin to prevent infections in newly diagnosed symptomatic myeloma

T2 - the TEAMM RCT

AU - Drayson, Mark T

AU - Bowcock, Stella

AU - Planche, Tim

AU - Iqbal, Gulnaz

AU - Pratt, Guy

AU - Yong, Kwee

AU - Wood, Jill

AU - Raynes, Kerry

AU - Higgins, Helen

AU - Dawkins, Bryony

AU - Meads, David

AU - Hulme, Claire T

AU - Whittaker, Anna C

AU - Hawkey, Peter

AU - Low, Eric

AU - Dunn, Janet A

PY - 2019/11

Y1 - 2019/11

UR - http://www.scopus.com/inward/record.url?scp=85074742321&partnerID=8YFLogxK

U2 - 10.3310/hta23620

DO - 10.3310/hta23620

M3 - Article

C2 - 31690402

SN - 1366-5278

VL - 23

SP - 1

EP - 94

JO - Health Technology Assessment

JF - Health Technology Assessment

IS - 62

ER -

Prophylactic levofloxacin to prevent infections in newly diagnosed symptomatic myeloma: the TEAMM RCT

ASJC Scopus subject areas

Access to Document

Research output

Levofloxacin prophylaxis in patients with newly diagnosed myeloma (TEAMM): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial

Cite this